SPDR Series Trust - State Street SPDR S&P Biotech ETF
ARCAXBI, the SPDR S&P Biotech ETF, enters the final days of September with a striking disconnect: options traders are at their most bearish in twelve months, yet the lending market has quietly loosened over the past week. The options picture is the sharpest signal right now. The put/call ratio hit 1.41 on Thursday — more than two standard deviations above its 20-day average of 1.24…
XBI utilization surges to 90.78%, highest level in 52 weeks, signaling intense borrowing demand in biotech ETF.
Snapshot as of 4 Oct 2026
XBI, the SPDR S&P Biotech ETF, enters the final days of September with a striking disconnect: options traders are at their most bearish in twelve months, yet the lending market has quietly loosened over the past…
XBI, the SPDR S&P Biotech ETF, carries one of the most unusual positioning setups in the US market right now — short interest that dwarfs the available float, yet a borrow cost that has been falling steadily for…
XBI has gained 5.2% this week, and the borrow market that was at crisis tightness just days ago has meaningfully loosened — the two moves together tell a coherent story about shorts under pressure. The lending market…
Three distinct signals are converging on XBI simultaneously. The biotech ETF's lending market is at its tightest in months. Cost to borrow has surged 71% in a week. And options traders are pulling back on puts at an…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for XBI — free to start on ORTEX.
Sign up for free →Open XBI on ORTEX